Lyka Labs is currently trading at Rs. 17.20, up by 0.05 points or 0.29% from its previous closing of Rs. 17.15 on the BSE.The scrip opened at Rs. 17.75 and has touched a high and low of Rs. 17.75 and Rs. 17.20 respectively. The BSE group `B` stock of face value Rs. 10 has touched a 52 week high of Rs. 35.25 on 02-Apr-2019 and a 52 week low of Rs. 14.60 on 15-Oct-2019.Last one week high and low of the scrip stood at Rs. 19.50 and Rs. 16.80 respectively. The current market cap of the company is Rs. 50.92 crore.The promoters holding in the company stood at 19.88%, while Institutions and Non-Institutions held 4.15% and 75.97% respectively.Lyka Labs has entered into loan agreement with International Asset Reconstruction Company (IARC) for restructuring of loans taken from Dena Bank and Kapol Cooperative Bank and additional project finance & working capital loan. The company has executed loan agreement on November 20, 2019.Lyka Labs (Lyka) is an India-based healthcare company. The Company is manufacture of lyophilized products. The primary segment of the company is business segment, which consists of pharmaceutical products /pharma related services.

Lyka Labs is currently trading at Rs. 52.35, up by 1.85 points or 3.66% from its previous closing of Rs. 50.50 on the BSE.The scrip opened at Rs. 52.45 and has touched a high and low of Rs. 52.75 and Rs. 51.85 respectively. So far 4,180 shares were traded on the counter.The BSE group `B` stock of face value Rs. 10 has touched a 52 week high of Rs. 78.00 on 21-Jul-2016 and a 52 week low of Rs. 45.00 on 23-May-2017.Last one week high and low of the scrip stood at Rs. 52.75 and Rs. 46.00 respectively. The current market cap of the company is Rs. 115.38 crore.The promoters holding in the company stood at 23.99%, while Institutions and Non-Institutions held 6.44% and 69.57% respectively.Lyka Labs has entered into out-licensing / technology transfer deal with a US based Generics Company. It has entered an out-licensing / technology transfer deal for a basket of 12 Sterile Injectable Formulations for Manufacturing, Sales & Distribution in the United State of America. The market size of the licensed formulations is approximately $ 1.4 billion, as per IMS MAT March 2017. The company will be eligible for a royalty on end sales. Going forward, the company will continue to explore opportunities to monetize its R&D capabilities in the regulated markets throughout-licensing partnerships. Lyka Labs is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions. The company offers various surgical disposables, such as syringes, surgical blades, cotton crepe bandage and first aid kits.

Lyka Labs has submitted the Shareholding Pattern for the Period Ended December 31, 2016. The above information is a part of company’s filings submitted to BSE.

Lyka Labs has informed that the Register of Members & Share Transfer Books of the Company will remain closed from September 21, 2016 to September 28, 2016 for the purpose of Annual General Meeting (AGM) of the Company to be held on September 28, 2016.The above information is a part of company’s filings submitted to BSE.

Lyka Labs is currently trading at Rs. 85.70, up by 0.75 points or 0.88% from its previous closing of Rs. 84.95 on the BSE.The scrip opened at Rs. 85.65 and has touched a high and low of Rs. 88.05 and Rs. 84.65 respectively. So far 31701 shares were traded on the counter.The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 142.90 on 26-Nov-2015 and a 52 week low of Rs. 50.25 on 28-Apr-2015.Last one week high and low of the scrip stood at Rs. 88.05 and Rs. 79.80 respectively. The current market cap of the company is Rs. 189.54 crore.The promoters holding in the company stood at 24.90% while Institutions and Non-Institutions held 0.84% and 74.27% respectively.Lyka Healthcare, a wholly owned subsidiary of Lyka Labs, has launched two domestic marketing divisions in the name of Enspan and Cerabelle. Enspan would be marketing Critical and Anesthesia range of Products and Cerabelle would be marketing Dermatology and Cosmetology range of Products. The said products would also be offered internationally in the 46 countries in which Lyka has its presence.Lyka Labs is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions. The company offers various surgical disposables, such as syringes, surgical blades, cotton crepe bandage and first aid kits.

Lyka Labs has informed that Lyka Healthcare, a wholly owned subsidiary of the company, has launched two domestic marketing divisions in the name of Enspan and Cerabelle. Enspan would be marketing Critical and Anesthesia range of Products and Cerabelle would be marketing Dermatology and Cosmetology range of Products. These products would also be offered internationally in the 46 countries in which Lyka has its presence.The above information is a part of company’s filings submitted to BSE.

Lyka Labs is currently trading at Rs 84.50, up by 1.80 points or 2.18% from its previous closing of Rs 82.70 on the BSE.The scrip opened at Rs. 83.30 and has touched a high and low of Rs. 86.15 and Rs. 82.00 respectively. So far 47134 shares were traded on the counter.The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 142.90 on 26-Nov-2015 and a 52 week low of Rs. 50.25 on 28-Apr-2015.Last one week high and low of the scrip stood at Rs. 85.50 and Rs. 78.70 respectively. The current market cap of the company is Rs. 183.59 crore.The promoters holding in the company stood at 24.90% while Institutions and Non-Institutions held 0.84% and 74.27% respectively.Lyka Healthcare, a wholly owned subsidiary of Lyka Labs, has launched two domestic marketing divisions in the name of Enspan and Cerabelle. Enspan would be marketing Critical and Anesthesia range of Products and Cerabelle would be marketing Dermatology and Cosmetology range of Products. The said products would also be offered internationally in the 46 countries in which Lyka has its presence.Lyka Labs is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions. The company offers various surgical disposables, such as syringes, surgical blades, cotton crepe bandage and first aid kits.

Lyka Labs has informed that the Board of Directors of the Company at its meeting held on March 11, 2016, have considered merger of Lyka Healthcare, a wholly owned subsidiary and Lyka Exports, a subsidiary with Lyka Labs Limited with effect from April 01, 2015.The above information is a part of company’s filings submitted to BSE.

Lyka Labs has informed about result of E-voting and Poll conducted at Annual General Meeting (AGM) of the Company held on December 30, 2015.The above information is a part of company’s filings submitted to BSE.

Lyka Labs has informed that at the 36th Annual General Meeting of the Company held on December 30, 2015, Kunal N. Gandhi is hereby appointed by the Shareholders as Chief Executive Officer of the Company with effect from January 01, 2016.The above information is a part of company’s filings submitted to BSE.

Lyka Labs has informed that the 36th Annual General Meeting (AGM) of the Company was held on December 30, 2015.The above information is a part of company’s filings submitted to BSE.

Lyka Labs is currently trading at Rs. 132.80, up by 4.20 points or 3.27 % from its previous closing of Rs. 128.60 on the BSE.The scrip opened at Rs. 130.00 and has touched a high and low of Rs. 133.90 and Rs. 129.50 respectively. So far 152900 shares were traded on the counter.The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 142.90 on 26-Nov-2015 and a 52 week low of Rs. 25.00 on 29-Dec-2014.Last one week high and low of the scrip stood at Rs. 132.50 and Rs. 122.20 respectively. The current market cap of the company is Rs. 289.16 crore.The promoters holding in the company stood at 23.30 % while Institutions and Non-Institutions held 0.76 % and 75.94 % respectively.Lyka Labs has decided to raise funds upto Rs 100 crore by way of issue of shares on Preferential basis/Qualified Institutional Placement (QIP)/convertible debentures and any other securities in one or more combination. The company has also decided to increase Authorized Capital from existing Rs 26 crore consisting of Equity Capital of Rs 24 crore and Preference Capital of Rs. 2 crore to Rs 32 crore consisting of Equity Capital of Rs 30 crore and Preference Capital of Rs 2 crore. The board of company at its meeting held on December 28, 2015 has approved for the same. An Extra Ordinary General Meeting of members of the Company is convened on January 21, 2016 to obtain approval of Shareholders to authorize the Board of Directors to alter capital clause of Memorandum of Association of the Company and to decide the mode, size and terms & conditions of issue of capital.Lyka Labs is engaged in the manufacture of pharmaceutical products. It also manufactures Veterinary products including injections, powders, creams and suspensions. The company offers various surgical disposables, such as syringes, surgical blades, cotton crepe bandage and first aid kits.